AI Issue 6 2017

Acquisition International - June 2017 87 Sanofi Genzyme is one of the main medicine production global companies for the treatment of rare diseases - and was the pioneer in discovery of treatments to genetic diseases as Gaucher disease - Fabry disease and Pompe disease. As a winner of the exclusive 2017 Business Elite Awards from Brazil, we interviewed Director for Health Policies - LATAM, Eliana Tameirão to find out more about the firm’s strong reputation. s one of main medicine production global companies for the treatment of rare diseases, Director for Health Policies - LATAM, Eliana Tameirão begins by telling us how it feels be in the 2017 Business Elite Awards for Brazil. “I am very happy seeing my work being recognised in this way, after 18 years of being in this field, and I would like to also say that we have the patient as our most important focus and the reason for our existence. Company: Sanofi Genzyme Name: Eliana Tameirão, Director for Health Policies - LATAM Email: [email protected] Web: en.sanofi.com Address: Av.Major Sylvio de Magalhães Padilha, 5200 Philadelphia 2º Andar, Jd. Morumbi São Paulo, 05693-000 Brazil Phone: +55 11 3874 9888 It’s All about the Patient A 1705AI63 “This recognition means a lot to us, due to the responsible and hard level of work done here. Everything we do is always approached with extreme care and dedication, both to the patients and employees who have stood by me at all times, giving the necessary support that the operation needed.” Eliana then details the firm’s reputation and her valuable insights into the pharmaceutical sector today. “Sanofi Genzyme has a respectable reputation within the scientific community, where we have received the Prize of Best Science Company in the USA for 15 consecutive years. For 9 consecutive years in Brazil, we were elected the accolade of the Best Company to Work For. “I believe that the pharmaceutical sector today demands a great volume of capital and long-term investments. Before this scenario, the regulatory environment needs to offer stability and safety, both of which are necessary to calm down the investors. Therefore, scenario changes do bring certain worry.” Ending the interview on an upbeat note, Eliana is delighted to share her insights into the opportunities and challenges that lie ahead for the industry, plus her aspirations for the firm’s future. “Brazil is undoubtedly one of the biggest medicines global markets, with a strong presence in the public sector. One of the greatest challenges for us is to guarantee the population access to innovative medicines. “My future aspirations for the firm in 2017 and beyond concern launching new revolutionary medicines, thus consolidating Sanofi Genzyme’s leadership in the pharmaceutical sector even more.” It’s All about the Patient